Ocular Therapeutix, Inc.NASDAQ: OCUL

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

· Issued by Ocular Therapeutix, Inc.

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p

Ocular Therapeutix, Inc. on 6ix

Story so far

Earlier from Ocular Therapeutix

Later from Ocular Therapeutix

All Ocular Therapeutix news releases